Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab
- 7 Downloads
Advances in cancer chemotherapy have increased the opportunities of treating patients with cancer with renal dysfunction. Here we report the case of a 64-year-old woman with recurrent colorectal cancer who was treated with bevacizumab (BEV) combination chemotherapy. Although proteinuria caused by BEV developed early during the treatment and her renal function gradually deteriorated, BEV combination chemotherapy could be continued for 48 cycles over 2.5 years for controlling disease progression without other adverse events such as hypertension, decreased serum albumin level, or edema. After BEV discontinuation, proteinuria gradually improved and further renal function deterioration was not observed. Because the therapeutic options available for metastatic colorectal cancer are limited, balancing the risks and benefits of continuing chemotherapy is important in cases of adverse events.
KeywordsColorectal neoplasms Renal insufficiency Risk assessment Proteinuria Bevacizumab
The authors express their sincere gratitude to all the staff members involved in this case. The authors would like to thank Enago (https://www.enago.jp) for the English language review.
Compliance with ethical standards
Conflict of interest
Manabu Muto received a research grant from Chugai Pharmaceutical Co Ltd. outside of this research.
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent was obtained from all patients for being included in the study.
- 5.Avastin Prescribing Information. [Internet]. [cited 2018 Nov 26]. https://www.gene.com/download/pdf/avastin_prescribing.pdf
- 6.Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer ( FIRE-3): a post-hoc analysis of tumour dynamics in the fi nal RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426–34.CrossRefGoogle Scholar